PF-03550096
Selective full CB2 agonist (human Ki 7.9 nM), orally active in a rat model of visceral hypersensitivity.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₉H₂₈N₄O₄
CAS 910376-39-5
- Family
- Synthetic CB receptor agonistResearch ligand or medicine
- Molar mass
- 376.40 g/mol
Updated on
In plain terms
PF-03550096 is a laboratory molecule that activates the CB2 receptor, found mostly outside the brain, notably in the immune system and the gut. In rats, it inhibited the lowering of the colonic pain threshold induced by an inflammatory agent. No use in humans was found.
Receptors and activity
Target network
- Activates
- Binds or modulates
The lower the cited value, the closer the target sits to PF-03550096: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-03550096.
Map sources
- Galiègue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem, 1995 (new tab)
- Ständer S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- CB2AgonistKi = 7.9 nM · human68 out of 100
Kikuchi et al., J Pharmacol Sci 2008: pharmacological evaluation of PF-03550096, a CB2 ligand, in vitro and in a rat model of visceral hypersensitivity (new tab) · human CB2 (7.9 ± 1.7 nM); rat CB2 47 ± 5.6 nM; full agonist in a cell assay (Kikuchi et al. 2008)
- CB1Binding (function not established)Ki = 1.5 µM · human31 out of 100
Omura et al., Bioorg Med Chem Lett 2008: structure-activity studies of benzimidazolone derivatives, novel selective CB2 agonists (values read in ChEMBL, document CHEMBL1150312) (new tab) · [3H]SR141716A displacement at human CB1 (value read in ChEMBL, Omura et al. 2008)
Pharmacology
PF-03550096 belongs to a strategy of cannabinoid pharmacology applied to pain: targeting the CB2 receptor rather than CB1. Kikuchi and colleagues describe in 2008 a compound of this class, built on a benzimidazolone core remote from the usual cannabinoid chemotypes. The measured affinity is high at the human CB2 receptor (Ki of 7.9 nM) and lower at the rat one (47 nM), and the compound behaves as a full agonist in a cell assay. The values read in ChEMBL for the structure-activity study of Omura et al. (2008) give a Ki of 1,459 nM at human CB1. Given orally to rats, it inhibited the TNBS-induced lowering of colonic pain threshold, an effect reversed by SR144528 (Kikuchi et al. 2008). No clinical study and no pharmacokinetic or safety data in humans were found in the sources consulted.
Key sources.
- Kikuchi et al., J Pharmacol Sci 2008: pharmacological evaluation of PF-03550096, a CB2 ligand, in vitro and in a rat model of visceral hypersensitivity (new tab)PMID 18270474
- Omura et al., Bioorg Med Chem Lett 2008: structure-activity studies of benzimidazolone derivatives, novel selective CB2 agonists (values read in ChEMBL, document CHEMBL1150312) (new tab)PMID 18440813
- PubChem, PF-03550096, CID 24857887 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It was produced in a Pfizer pharmaceutical research programme; no clinical development or marketing was found in the sources consulted.
Origin
Laboratory synthesis
No known biosynthetic pathway: a synthetic molecule. It is a benzimidazol-2-one carboxamide, N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-3-(3-hydroxy-3-methylbutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide (name from the title of Kikuchi et al. 2008).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No commercialisation or marketing authorisation was found.
- France
Not classified: PF-03550096 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a benzimidazol-2-one carboxamide, which is not a 2-benzylated benzimidazole) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No commercialisation or marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › Research ligand or medicine
- Class
benzimidazolone-carboxamide
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Kikuchi et al., J Pharmacol Sci 2008: pharmacological evaluation of PF-03550096, a CB2 ligand, in vitro and in a rat model of visceral hypersensitivity (new tab)PMID 18270474
- Omura et al., Bioorg Med Chem Lett 2008: structure-activity studies of benzimidazolone derivatives, novel selective CB2 agonists (values read in ChEMBL, document CHEMBL1150312) (new tab)PMID 18440813
- PubChem, PF-03550096, CID 24857887 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(3-hydroxy-3-methylbutyl)-2-oxobenzimidazole-1-carboxamide
- Other names
- PF 03550096 · PF-3550096
Identifiers
- Formula
- C₁₉H₂₈N₄O₄
- CAS
- 910376-39-5
- PubChem CID
- 24857887(new tab)
- InChIKey
- GGNIFXBIJCNXCT-CQSZACIVSA-N
- SMILES
- CC(C)
(C) [C@@H] (C(= O) N) NC(= O) N1C2= CC= CC= C2N(C1= O) CCC(C) (C) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.